Adrenergic-cholinergic imbalances: the physostigmine-syndrome is not antagonized by the MAO-A inhibitor brofaromine

Adrenergic-cholinergic imbalances: the physostigmine-syndrome is not antagonized by the MAO-A inhibitor brofaromine
复制标题

肾上腺素能-胆碱能失衡:MAO-A 抑制剂溴法罗明不能拮抗毒扁豆碱综合征

DOI:
10.1016/0924-977x(90)90006-v
复制
发表时间:
1990
影响因子:
5.6
通讯作者:
R. Peter
R. Peter
中科院分区:
医学2区
文献类型:
--
作者:
J. Fritze;E. Sofić;H. Pfüller;M. Lanczik;R. Peter

文献摘要

参考文献

被引文献

相似文献

中枢活性胆碱酯酶抑制剂毒扁豆碱诱导的行为综合征被认为是一种自发性抑郁症的模型。在6名健康志愿者的急性试验中,该模型抑郁症伴有明显的心血管、代谢和神经内分泌应激现象。然而,从基线的变化程度,几乎没有相关的行为和生理现象。行为和生理现象不能拮抗溴法罗明,一个假定的抗抑郁药可逆性和选择性抑制单胺氧化酶A(MAO-A),对比完全抑制中枢胆碱溶解东莨菪碱。这进一步证明了抗抑郁药的疗效取决于继发于胺能神经传递增强的长期适应性变化,而不是这种增强本身。
The centrally active cholinesterase inhibitor physostigmine induces a behavioral syndrome which is thought to represent a model of spontaneous depression. In the present acute trial in 6 healthy volunteers, this model depression was accompanied by clearcut cardiovascular, metabolic and neuroendocrine phenomena of stress. The extent of the changes from baseline, however, scarcely correlated between the behavioral and physiologic phenomena. The behavioral and physiological phenomena could not be antagonized by brofaromine, a putative antidepressant reversibly and selectively inhibiting monoamine oxidase A (MAO-A), contrasting to the complete inhibition by the central cholinolytic scopolamine. This is further evidence that antidepressant efficacy depends on long-term adaptive changes secondary to the enhancement of aminergic neurotransmission rather than this enhancement itself.
毒扁豆碱对脉搏、血压和血清肾上腺素水平的影响。
DOI: 10.1176/ajp.142.6.738
发表时间: 1985
期刊: The American journal of psychiatry
影响因子: --
作者:
Janowsky,DS;Risch,SC;Huey,LY;Kennedy,B;Ziegler,M
通讯作者: Ziegler,M